Functional B1-cells that have been derived from mouse embryonic stem cells have been found to be capable of long-termÂ engraftment as they secreteÂ natural antibodies after transplantation.
Scientists were interested in B1-cells generated from pluripotent stem cells because they could be tested as a therapeutic for a broad range of immunological disorders.
“It is still challenging to produce transplantable immune cells from mouse embryonic stem cells, so obtaining transplantable functional B1-cells from mouse embryonic stem cells is a significant advance in the field,” said senior study author Dr Momoko Yoshimoto of the Center for Stem Cell & Regenerative Medicine at the McGovern Medical School at UTHealth in Houston. “The take-home message is that a portion of immune cells may be replaced by cell therapies utilising pluripotent stem cells in the future.”
Hematopoietic stem cells in the adult bone marrow – the soft, sponge-like tissue in the center of most bones – provide various blood cells throughout life. Hematopoietic stem cell transplants are now routinely used to treat patients with cancers and other disorders of the blood and immune systems. But with current in vitro methods, it is challenging to produce hematopoietic stem cells that recapitulate the properties of cells in living organisms without gene manipulation.
In particular, bone marrow transplantation may fail to reconstitute some immune cells called B1-cells, which produce immunoglobulin M (IgM) antibodies – the first type of antibody the immune system makes to fight a new infection. In addition to patients who receive stem cell transplants, IgM deficiency also occurs in individuals with some cancers, autoimmune diseases, allergic diseases, and gastrointestinal diseases, increasing the risk for life-threatening infections.
In the new study, Dr Yoshimoto and her colleagues demonstrated that functional, transplantable B1-cells can be generated from mouse embryonic stem cells without gene modifications. The researchers overcame previous barriers preventing this feat by using high-quality cell lines to support B-cell development. After being transplanted into recipient mice, stem cell-derived B progenitors matured into B1-cells that were maintained for more than 6 months and secreted natural IgM antibodies.
“Producing functional B1 progenitors in vitro from mouse embryonic stem cells is an important step to develop a cell therapy to provide natural IgM and innate B1-cells that may not be provided by bone marrow transplantation,” Dr Yoshimoto said.
In future studies, the researchers will attempt to generate B-cells from human induced pluripotent stem cells, which may be used for cell therapy to treat patients with immunological disorders. “This is just a first step in a long process to translate our findings to humans,” Dr Yoshimoto said.
The study was published in the journalÂ Stem Cell Reports.